These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14635366)

  • 1. Inotropic therapy is unsuccessful: wrong conceptual target or wrong therapeutic tools?
    Rapezzi C; Perugini E; Santi M; Bracchetti G; Branzi A
    Ital Heart J; 2003 May; 4 Suppl 2():22S-26S. PubMed ID: 14635366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Positive inotropic substances--therapeutic perspectives].
    Erdmann E; Böhm M
    Z Kardiol; 1991; 80 Suppl 8():57-62. PubMed ID: 1796636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel approach to the development of positive inotropic agents for chronic heart failure.
    Packer M
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S52-6. PubMed ID: 8907131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotropic therapy for heart failure: an evidence-based approach.
    Felker GM; O'Connor CM
    Am Heart J; 2001 Sep; 142(3):393-401. PubMed ID: 11526351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of congestive heart failure: is the role of positive inotropic therapy fading?
    Futterman LG; Lemberg L
    Am J Crit Care; 1996 Nov; 5(6):455-60. PubMed ID: 8922162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
    Erhardt LR
    Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotropes in the management of acute heart failure.
    Petersen JW; Felker GM
    Crit Care Med; 2008 Jan; 36(1 Suppl):S106-11. PubMed ID: 18158469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic effects of calcium-sensitizing agents.
    Vegh A; Papp JG; Udvary E; Kaszala K
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S20-31. PubMed ID: 8907128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia?
    Young JB
    Pharmacotherapy; 1996; 16(2 Pt 2):78S-84S. PubMed ID: 8668609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure.
    Katz AM
    Circulation; 1986 Mar; 73(3 Pt 2):III184-90. PubMed ID: 2417747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will calcium sensitizers play a role in the treatment of heart failure?
    Nielsen-Kudsk JE; Aldershvile J
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S77-84. PubMed ID: 8907135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
    Feldman AM; Oren RM; Abraham WT; Boehmer JP; Carson PE; Eichhorn E; Gilbert EM; Kao A; Leier CV; Lowes BD; Mathier MA; McGrew FA; Metra M; Zisman LS; Shakar SF; Krueger SK; Robertson AD; White BG; Gerber MJ; Wold GE; Bristow MR;
    Am Heart J; 2007 Nov; 154(5):861-9. PubMed ID: 17967591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Refractory heart failure. Positive inotropes and beta blockers: alternative or complementary treatments?].
    Sabbadini G; Ciaccheri M; Castelli G; Sinagra G; Di Lenarda A
    Ital Heart J Suppl; 2002 Aug; 3(8):804-11. PubMed ID: 12407835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion therapy in severe heart failure. A reappraisal.
    Campana C; Scelsi L; Serio A
    Ital Heart J; 2003 May; 4 Suppl 2():15S-21S. PubMed ID: 14635365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New inotropic drugs in chronic cardiac insufficiency: progress or wrong track].
    Asseman P; Pruvost P; Lesenne M; Adnet P; Leroy F; Vigne JM; Delvallez L; Lacroix D; Thery C
    Ann Cardiol Angeiol (Paris); 1988 Mar; 37(3):153-61. PubMed ID: 3284451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M; Pignataro C; Fraticelli A; Mebazaa A
    Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.